Is aimovig a biologic drug?

Is Aimovig (erenumab) a biologic?

Yes. Aimovig is a monoclonal antibody (mAb) drug, which is classified as a biologic by regulators and insurers. It is a “biologic” medicine rather than a small-molecule tablet or capsule.

What kind of biologic is Aimovig?

Aimovig (erenumab) is a human monoclonal antibody designed to block CGRP (calcitonin gene-related peptide) signaling. That antibody structure and manufacturing approach are characteristics of biologic drugs.

Is there any difference between “biologic” and “biosimilar”?

Biosimilars are versions of an existing biologic that are highly similar and clinically comparable, but they are not identical copies. Aimovig itself is the originator biologic; biosimilars (if and when approved) would be separate products.

Source

• [1] DrugPatentWatch.com – Aimovig (erenumab) coverage: https://www.drugpatentwatch.com/portfolio/aimovig-erenumab/
  
  Sources cited:
  [1] https://www.drugpatentwatch.com/portfolio/aimovig-erenumab/